A couple riding bikes along a seaside path

Melanocortin Agonist

PT-141 10mg

Sexual Wellness & Arousal Enhancement

PT-141 is a melanocortin receptor agonist that supports sexual arousal and desire in both men and women by activating pathways in the central nervous system—offering a unique approach to sexual wellness that works through the brain rather than vascular mechanisms.

10mg

Per Vial

SC/IM

Administration

MC4R

Receptor Target

22+

BHRC Locations

PT-141 10mg

A melanocortin receptor agonist peptide designed to support sexual arousal and desire through central nervous system activation.

What is PT-141?

PT-141, also known as Bremelanotide, is a synthetic peptide that acts as a melanocortin receptor agonist with a specific affinity for MC4R receptors in the brain. Unlike traditional treatments that focus on vascular mechanisms, PT-141 works through the central nervous system to influence sexual desire and arousal.

Originally developed from the peptide Melanotan II, PT-141 was refined to specifically target sexual function without the unwanted side effects. It activates melanocortin receptors involved in sexual motivation, desire, and arousal—making it effective for both men and women experiencing low libido or arousal difficulties.

Clinical research led to FDA approval of bremelanotide (Vyleesi) for one indication in premenopausal women; BHRC's 10mg vial is compounded and other uses are off-label. At BHRC, our physicians use PT-141 as part of comprehensive sexual wellness protocols, customized to each patient's unique needs and health profile.

Book a Consultation
A couple laughing on a picnic blanket in a green park

The Melanocortin Receptor Mechanism

PT-141 activates specific melanocortin receptors in the brain, triggering pathways that enhance sexual desire and arousal through central nervous system modulation.

MC4R Activation

Binds to melanocortin-4 receptors in the hypothalamus and other brain regions involved in sexual behavior, triggering the cascade that leads to increased desire and arousal.

CNS-Mediated Response

Works through the central nervous system rather than peripheral vascular mechanisms—addressing sexual desire at its neurological source for both psychological and physiological effects.

Enhanced Arousal

Supports natural sexual response by enhancing neurological pathways associated with arousal, desire, and sexual motivation—effective for a wide range of sexual wellness concerns.

Why Consider PT-141?

Enhanced Sexual Desire

Supports increased libido and sexual motivation by activating brain pathways responsible for desire—addressing low libido at its neurological source.

Improved Arousal Response

Enhances the natural physiological arousal response in both men and women—supporting better sexual performance and satisfaction through CNS activation.

Effective for Both Sexes

Studied in both men and women; the FDA-approved brand is indicated only for premenopausal women, and use in men is off-label.

Central Mechanism

Works through brain pathways rather than vascular mechanisms, which sets it apart from erectile dysfunction medications.

Rapid Onset

Effects typically begin within 45-60 minutes of administration and can last several hours—allowing for spontaneous intimate encounters with proper planning.

Relationship Benefits

Supports improved intimacy and relationship satisfaction by addressing underlying desire and arousal concerns—enhancing overall sexual wellness and quality of life.

Close-up of a woman's smile on a white background

Getting Started with PT-141

1

Consultation

Meet with a BHRC physician to discuss your sexual wellness goals and determine if PT-141 is appropriate for your needs.

2

Lab Work

Complete comprehensive lab testing to rule out underlying conditions and assess treatment candidacy.

3

Treatment Plan

Receive your personalized PT-141 protocol with clear dosing instructions, administration guidance, and timing recommendations.

4

Follow-Up

Regular check-ins to assess response, optimize dosing, and adjust your protocol for best results and satisfaction.

Woman running on a coastal trail at sunrise, smiling

Evidence-Based Approach

At BHRC, patient safety is paramount. PT-141 is administered only after thorough medical evaluation, comprehensive screening, and confirmation of treatment candidacy by our experienced physicians specializing in sexual wellness.

  • Medical Supervision: All treatments are prescribed and monitored by licensed physicians with expertise in sexual health and peptide therapy.
  • Comprehensive Screening: Thorough evaluation to identify contraindications and ensure PT-141 is appropriate for your health profile.
  • Personalized Protocols: Individualized dosing tailored to your response, health status, and sexual wellness goals.
  • Quality Assurance: Sourced from reputable compounding pharmacies with strict quality control and pharmaceutical standards.
Discuss Safety Profile

22+

BHRC locations providing comprehensive sexual wellness care

Physician

Supervised treatment protocols and ongoing monitoring

Quality

Verified sourcing and pharmaceutical-grade peptide standards

Stephanie Starin, NP, nurse practitioner at Beverly Hills Rejuvenation Center
Free virtual consult
Talk to Stephanie Starin, NP, from home
A free 60-minute video visit. Ask about peptide therapy or medical weight loss, get your questions answered, and leave with a plan from a licensed provider.
Book now

At a glance

PT-141 at BHRC: the essentials

What it is
PT-141 is the research name for bremelanotide, a melanocortin receptor agonist. The 10mg on this page is the total amount in a compounded multi-dose vial.
The approved version
Bremelanotide is FDA-approved as Vyleesi, an autoinjector, for one indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women.
How it is given
A subcutaneous injection taken on demand, ahead of anticipated sexual activity, rather than every day.
Who asks about it
Adults with a persistent, distressing drop in sexual desire, and men or postmenopausal women curious about it outside the approved label.
Typical course
A short trial of a few uses with a follow-up to review effect, nausea and blood pressure before any refill.
Regulatory status
Bremelanotide is FDA-approved as Vyleesi; BHRC's 10mg vial is a compounded preparation that is not FDA-approved.
Man hiking a sunny mountain ridge trail with a daypack

Your plan

What a PT-141 plan at BHRC involves

1

A private, specific consultation

Low desire has many causes: relationship stress, depression and anxiety, medications such as some antidepressants and blood pressure drugs, hormonal changes, pain during sex and medical conditions. The BHRC clinical team asks about each of these, because a drug that acts on desire will not fix a cause that sits elsewhere, and some causes need their own treatment first. You can bring a partner to the visit if you want to, but you do not have to; some people find it easier to talk about this alone first.

2

Blood pressure and cardiovascular screen

Bremelanotide can raise blood pressure briefly after a dose, so your blood pressure is measured and your heart history reviewed. Uncontrolled high blood pressure or known cardiovascular disease rules it out at BHRC. Relevant labs, such as hormone levels when symptoms suggest a hormonal cause, are ordered as needed.

3

Choosing the product and route

If PT-141 is a reasonable fit, the provider explains the difference between the FDA-approved autoinjector and BHRC's compounded vial, including that use outside the approved label is off-label. You leave with written instructions on timing, storage, injection technique and how far apart doses must be. The dose is set by the provider.

4

First-use plan

Many people are advised to try the first dose at a calm time at home, not before an important evening, so they know how their body reacts, particularly to nausea and flushing. The provider may suggest how to manage nausea if it occurs. Avoiding a heavy meal or alcohol around the first dose is a common practical tip, and you should not drive until you know how you react.

5

Follow-up before refills

After a few uses, the clinic reviews whether desire or arousal changed in a way that matters to you, any side effects, and a blood pressure check. If there was no meaningful benefit, the honest recommendation is usually to stop rather than escalate. If there was a partial benefit, the provider may adjust timing before considering any change in dose, because timing relative to activity is often what people get wrong first.

Timeline

What to expect with PT-141, step by step

  1. After a dose

    In the approved product's trials, effects are designed to be used ahead of sexual activity; nausea, flushing and headache, when they happen, usually appear within the first hours and pass.

  2. First few uses

    The response is variable. Some people notice increased interest or arousal, some notice side effects only, and some notice nothing.

  3. By the follow-up visit

    Enough experience to judge whether it is worth continuing. The approved label advises stopping if there is no improvement after eight weeks.

  4. Longer term

    On-demand use continues only if it is helping and side effects stay acceptable, with periodic blood pressure checks and a watch for skin darkening.

Compare

PT-141 compared with other options

OptionHow it actsUse patternStatus
PT-141 10mg vial (this page)Brain melanocortin receptors (desire and arousal)On demand, injectedCompounded; not FDA-approved
Vyleesi (bremelanotide autoinjector)Same moleculeOn demand, injectedFDA-approved for HSDD in premenopausal women only
PDE5 inhibitors (sildenafil, tadalafil)Blood flow to erectile tissueOn demand or daily, oralFDA-approved for erectile dysfunction in men
KisspeptinReproductive hormone axisClinic-guided trialNot FDA-approved; FDA 503A Category 2
Sex therapy or couples counselingPsychological and relational factorsSessionsStandard care

Is it right for you?

Who PT-141 may suit, and who should not use it

May be a fit if

  • Premenopausal women with a long-standing, distressing loss of desire that is not explained by another condition, for whom the approved product's label also applies
  • Adults who have had other causes of low desire reviewed and want a supervised trial
  • People with normal, well-controlled blood pressure and no known heart disease
  • Patients comfortable with an on-demand injection and with stopping if it does not help

Not a fit if

  • Uncontrolled high blood pressure or known cardiovascular disease
  • Pregnancy or breastfeeding
  • Taking oral naltrexone for alcohol or opioid use disorder, since bremelanotide can significantly lower naltrexone levels
  • Taking oral medicines that must reach a set blood level quickly, such as some antibiotics, because bremelanotide can slow stomach emptying
  • A history of melanoma or concerning moles, given the melanocortin pathway's link to skin pigment
  • Anyone under 18
  • Women who could become pregnant and are not using effective contraception; the label advises contraception and stopping if pregnancy is suspected
  • People looking for a performance enhancer; the approved label specifically says bremelanotide is not indicated to enhance sexual performance

Monitoring

How BHRC monitors PT-141

Blood pressure is the main safety marker. The approved label describes a transient rise in blood pressure and a small fall in heart rate after each dose, peaking two to four hours later and usually resolving within 12 hours, and an analysis of the development program advised caution in anyone at cardiovascular risk. BHRC checks blood pressure at the consult and at follow-up and asks you to report headaches, chest discomfort or palpitations after a dose.

Nausea is the most common reason people stop. The Vyleesi label reports nausea in 40% of patients in the phase 3 program, with 8% stopping early because of it, and notes that it improved for most people with the second dose. Flushing and headache are the next most common effects. If nausea is severe or you vomit, call the clinic before using it again.

Skin darkening, especially on the face, gums or breasts, has been reported with repeated use, and the Vyleesi label reports it in about 1% of patients using up to eight doses a month, with a higher risk with daily dosing and in people with darker skin; in some cases it did not resolve. Report any new pigmentation. Because this is a melanocortin drug, BHRC also asks about moles and skin cancer history before prescribing and at reviews.

Regulatory status

PT-141: FDA status and how it is prescribed

Regulatory status: Bremelanotide is FDA-approved under the brand name Vyleesi, an autoinjector indicated only for premenopausal women with acquired, generalized hypoactive sexual desire disorder; the label states it is not indicated for postmenopausal women, men, or to enhance sexual performance. The PT-141 10mg vial on this page is a compounded preparation; compounded drugs are not FDA-approved and FDA does not review them for safety, effectiveness or quality. Use outside the approved label is off-label. BHRC prescribes PT-141 only after a consultation, a blood pressure check and a medication review with a licensed provider. This page does not claim that PT-141 treats, cures or prevents any sexual or medical condition beyond the approved label. Prepared by the BHRC team from FDA and PubMed sources.

Before you book

PT-141: cost, consultation and safety questions

What is PT-141 and how does it work?

PT-141, or bremelanotide, is a synthetic peptide related to alpha-melanocyte-stimulating hormone. It activates melanocortin receptors in the brain, especially the MC4 receptor, which is involved in sexual motivation. It does not work by increasing blood flow the way erectile dysfunction pills do, which is why it is described as acting on desire rather than mechanics. The approved label notes that how long each dose lasts, and the ideal window for taking it, have not been fully worked out, so some trial and error with timing is normal.

Is PT-141 FDA-approved?

The molecule is, under a specific brand and label. Bremelanotide was approved in 2019 as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The approved label says it is not indicated for postmenopausal women, men, or to enhance sexual performance. BHRC's 10mg vial is compounded and is not FDA-approved, and any use outside that label is off-label.

Does PT-141 work for men?

There is some research. A 2008 randomized trial in men whose erectile dysfunction did not respond to sildenafil reported more positive responses with bremelanotide than placebo, along with more side effects. Bremelanotide has not been approved for men, and the evidence is far thinner than for standard erectile dysfunction treatments, which your provider will discuss as well. If erections are the main concern rather than desire, a PDE5 inhibitor or an evaluation for an underlying cause is usually the more evidence-based first step.

What did the main trials in women find?

Two phase 3 trials involving more than 1,200 premenopausal women with HSDD found statistically significant, modest increases in sexual desire and reductions in related distress compared with placebo. Nausea, flushing and headache were more common with bremelanotide. Later subgroup analyses found similar patterns across age, weight and contraceptive use.

Where can I find PT-141 dosing?

Your provider sets the dose and the minimum gap between doses at the consult. For general background on how PT-141 is used and how the vial is handled, see our PT-141 Dosage Guide. It is educational, not a prescription.

What does PT-141 cost at BHRC?

Cost depends on whether a compounded vial or the brand product is appropriate, how often you expect to use it, and the follow-up visit. BHRC does not post prices here; you receive a quote after the consultation. The brand autoinjector may be partly covered by some insurance plans for its approved indication, while compounded vials generally are not.

What are the side effects?

The most common are nausea, flushing, headache and injection-site reactions. Blood pressure can rise briefly after a dose. Skin darkening has been reported with repeated use. Serious reactions are uncommon in trials but anything unexpected should be reported. The label also limits use to one dose within 24 hours and no more than eight doses a month, partly to limit blood pressure effects and pigmentation risk; your plan will include a similar ceiling.

Can I use it with my other medications?

Tell your provider about everything you take. Bremelanotide can lower blood levels of oral naltrexone, which can make naltrexone less effective, and it can slow stomach emptying, which may affect some oral drugs. Blood pressure medications and antidepressants are reviewed too.

How is it different from Melanotan II?

Both act on melanocortin receptors, and bremelanotide was developed from the same research line. Melanotan II has broader effects, including on skin pigment, and FDA has published serious safety concerns about compounded Melanotan II. Bremelanotide is the one with an approved product and a published safety program.

Can I get it without a consultation?

Not at BHRC. A consultation is required because blood pressure, cardiovascular history, pregnancy status and medication interactions all affect whether it is safe for you.

Selected research

Published research on PT-141

The literature below is peer-reviewed background on PT-141 and the mechanisms discussed on this page, so you can read the primary sources yourself. It is not evidence of any particular outcome at BHRC, and some of it is preclinical work in animals or cells. Your provider will discuss what the evidence does and does not support for your situation.

  1. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol (2019). PubMed 31599840
  2. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt) (2022). PubMed 35147466
  3. Bremelanotide: First Approval. Drugs (2019). PubMed 31429064
  4. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol (2008). PubMed 18206919
  5. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health (Larchmt) (2022). PubMed 35230162
  6. Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. Mayo Clin Proc (2017). PubMed 27916394
  7. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med (2019). PubMed 31277966

PT-141 FAQ

What is PT-141?

PT-141 (Bremelanotide) is a melanocortin receptor agonist peptide that enhances sexual desire and arousal by activating MC4R receptors in the brain. Unlike traditional treatments, it works through the central nervous system to address low libido in both men and women.

How is PT-141 administered?

PT-141 is administered via subcutaneous injection, typically 45-60 minutes before anticipated sexual activity. Your BHRC physician will provide detailed injection training and dosing instructions based on your individual protocol.

What are the benefits?

PT-141 supports enhanced sexual desire, improved arousal response, and better sexual satisfaction. It has been studied in both men and women and works through central pathways. Individual results vary.

Who is a good candidate?

Ideal candidates are adults experiencing low libido, reduced sexual desire, or arousal difficulties not fully addressed by other treatments. A BHRC physician will evaluate your medical history, sexual health concerns, and overall wellness to determine if PT-141 is appropriate for you.

Are there side effects?

Common side effects may include temporary flushing, nausea, or headache. Some patients experience increased blood pressure or skin darkening with prolonged use. Your BHRC physician will discuss all potential side effects, contraindications, and monitoring protocols during your consultation.

How long until I see results?

PT-141 typically begins working within 45-60 minutes of administration, with effects lasting several hours. For best results, patients should plan administration timing based on anticipated activity. Response varies by individual, and your physician will help optimize timing and dosing for your needs.

Begin Your Transformation

Schedule a consultation with our medical team to learn if PT-141 peptide therapy is right for your sexual wellness journey.

"*" indicates required fields

This field is hidden when viewing the form
Appointment & Account Texts (optional)
Promotional Texts (optional)
Stephanie Starin, NP, nurse practitioner at Beverly Hills Rejuvenation Center
Free virtual consult
Talk to Stephanie Starin, NP, from home
A free 60-minute video visit. Ask about peptide therapy or medical weight loss, get your questions answered, and leave with a plan from a licensed provider.

Or call us directly: +1 213-325-3373

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult with a qualified healthcare professional before beginning any supplementation program. PT-141 is available only through licensed medical providers. BHRC physicians will evaluate your candidacy based on comprehensive medical assessment and health screening.